The intravenous administration of 3 or 5 mg of glucagon to 13 patients with heart disease resulted in a statistically significant increase in heart rate, cardiac index, stroke power index, mean rate of left ventricular ejection, and maximum rate of rise of left ventricular pressure, whereas systemic vascular resistance declined. A moderate increase in mean stroke volume index and stroke work index and a slight fall in left ventricular end-diastolic pressure also occurred, although these changes were not statistically significant. The increase in cardiac index averaged 19%, with nine of the patients demonstrating an increase exceeding 10% of their respective control value. These effects of glucagon generally reached a maximum within 15 min after drug administration and also were of short duration.
Supported in part with facilities provided by Research Grant HE-06308 from the National Heart Institute, U. S. Public Health Service, Postgraduate Cardiovascular Research Training Grant HTS-5363 from the National Heart Institute and the Indiana Heart Association. 38 centered on the cardiovascular changes which it may produce. It has been observed that glucagon produces both positive chronotropic and positive inotropic effects on isolated cardiac muscle,2-4 in heart-lung preparations2 and in the intact animal.3-5 In addition, Parmley and associates have reported that glucagon produces similar effects in man. 6 To provid further information regarding this potentially useful action of glucagon in patients with heart disease, the following study was performed.
was placed in the right ventricle and a no. 8 NIH catheter was inserted retrogradely into the left ventricle. Brachial arterial pressure and the pressures in the above chambers were measured with Statham P23Db transducers with the midthoracic level used as the zero reference point. Cardiac output was determined 'by the indicatordilution method with the injection of indocyaninegreen dye into the right ventricle and sampling from the brachial artery. The first derivative of left ventricular pressure was determined with an R-C differentiating circuit. The left ventricular systolic ejection time was measured from an indirect carotid arterial tracing or simultaneously measured left ventricular and brachial artery pressure curves recorded at a paper speed of 100 mm/ sec. After heart rate, systemic arterial pressure, and left ventricular end-diastolic pressure had remained constant for 15 to 20 min, 3 or 5 mg of glucagon was injected intravenously over approximately 30 sec.* The above variables were then recorded 5, 15, 30 and 60 min after completion of glucagon administration.
Stroke work index (SWI) was calculated from the following formula:
SWIing-m/m2=~1 00 where SVI equals the stroke volume index in mI/M2, LVSP, the mean left ventricular pressure during ejection in mm Hg determined by planimetric integration, and LVEDP, left ventricular end-diastolic pressure in mm Hg. Stroke power *Glucagon was kindly supplied by Eli Lilly and Company, Indianapolis, Indiana.
index (SPI) in g-m/sec/m2 was calculated by dividing SWI by the systolic ejection period in seconds. The mean rate of left ventricular ejection in ml/sec/m2 was determined by dividing SVI by the systolic ejection period in seconds. Systemic vascular resistance in dynes sec cm-5 was calculated according to the standard formula with the exception that right ventricular enddiastolic pressure rather than mean right atrial pressure was subtracted from the mean systemic arterial pressure. All pressures were averaged over at least two complete respiratory cycles.
To compare the effect of glucagon in these patients with that of an agent with known positive inotropic actions, eight patients received a constant infusion of isoproterenol at the end of the 60-min glucagon study period. An attempt was made to obtain as great an inotropic effect as possible with isoproterenol under these conditions by infusing at the maximum rate that the patient would safely tolerate without an inordinate fall in systemic arterial pressure, marked increase in sinus rate, or production of arrhythmia. The infusion rate varied from 3 to 8 lug/ min, and when systemic arterial pressure, heart rate, and LVEDP had been constant from 3 to 5 min, hemodynamic measurements were made.
Statistical analyses were performed using Student's t test with paired observations. 7 The clinical characteristics of each patient are presented in table 1 . Each patient had radiographic evidence of cardiomegaly or electrocardiographic changes of left ventricular hypertrophy. The patients ranged in age from 34 to 63 years (average, 48). Nine of the patients had had congestive heart failure prior to the study, and eight were receiving a digitalis preparation. 3 . This reveals that a significant increase in cardiac index, averaging 19%, was accompanied by a significant increase in SPI, mean rate of left ventricular ejection (MRE), and maximum LV dp/dt, as well as a significant decrease in systemic vascular resistance (SVR). Although a slight decrease in LVEDP and an A comparison of the effect of glucagon and isoproterenol in eight patients, four of whom received 3 mg of glucagon and the other four, 5 mg, is given in table 4. Three and 5 mg of glucagon resulted in an average maximum increase in cardiac output of 13 and 16%, respectively, whereas isoproterenol in doses of 3 and 8 ,ug/min produced an increase averaging 21% in the former and 23% in the latter group. A greater reduction in LVEDP followed administration of isoproterenol than either of the doses of glucagon. The marked increase in heart rate and decrease in resistance to left ventricular ejection that occurred with isoproterenol, however, prohibits any comparison of the direct inotropic effect of these two agents.
Blood glucose and plasma potassium values 30 min after administration of glucagon were determined in eight patients, four of whom received 3 mg and the other four, 5 mg. Results are given in table 5. As expected, blood glucose increased in each of these patients, and this effect was more pronounced after injection of 5 mg than of 3 mg of glucagon. In addition, a decrease in plasma potassium occurred in each patient, averaging 0.3 mEq/L after 3 mg and 0.8 mEq/L The magnitude of the hemodynamic changes and the time at which the maximum changes occurred after glucagon varied considerably among patients and was seemingly unrelated to the severity or duration of the heart disease. However, significant hemodynamic improvement occurred in most of these 162 (table 3) , the increase in cardiac output was accompanied by a statistically significant increase in those variables reflecting primarily the velocity of myocardial contraction, that is, SPI, MRE, and maximum left ventricular dp/dt without a significant change in heart rate, systemic arterial pressure, or LVEDP. The fact that the increases in SVI and SWI were not statistically significant need not detract from the conclusion that glucagon does produce a positive inotropic effect. Others have demonstrated that changes in the contractile state of the myocardium can occur which will not affect the mechanical work performed by the ventricle but which will alter those variables reflecting the rate with which work is performed.9' 10 Furthermore, changes in the relationship of mechanical work performed and the rate of performing work to changes in LVEDP ( fig. 2 ) provide additional evidence that glucagon did produce a positive inotropic effect in most of our patients.
The mechanism responsible for the increase in cardiac output in the patients in whom definitive evidence of a positive inotropic action of glucagon was not observed is unclear. It is possible that changes in the contractile state of the myocardium might have occurred which were not of sufficient magnitude to produce changes in the variables used to assess myocardial function in the present study, as others have demonstrated in animals.10 Also it is possible that glucagon may exert peripheral effects, for example, an effect on capacitance vessels and an increase in venous return, which at present are unrecognized.
Only minor differences are evident between the results of this study and the observations of Parmley and associates on patients receiving similar doses of glucagon.6 These investigators observed positive chronotropic and inotropic effects of glucagon more consistently than they were observed in the present study, although the magnitude and duration of the changes in CI and LVEDP in these two studies generally are comparable. They also reported that systemic arterial pressure was increased and systemic vascular resistance was unchanged after glucagon, whereas in this study systemic vascular resistance was reduced and systemic arterial pressure was essentially unchanged. Their observations also were made in patients with a wider variety of heart diseases than those of this study.
Initially, our study was designed to determine the effect of glucagon at two different dosages. Seven patients were given 3 mg of glucagon and six patients were given 5 mg. For comparative purposes the results in these two groups are illustrated in figure 2 . The values represent those existing at the time of the maximum increase in cardiac output. Five milligrams of glucagon did result in a greater increase in cardiac index, averaging 26% above control values as opposed to 12% with 3 mg, and a somewhat greater increase in SVI, SWI, SPI, and MRE. However, as stated earlier, it is apparent that the two groups are not comparable and that the severity of the heart disease as judged by the resting CI and LVEDP was significantly greater in the group receiving 5 mg. Thus, it is not possible to determine precisely whether the greater hemodynamic effect of 5 mg of glucagon represents the effects of a larger dose or the response of the myocardium whose function is more severely impaired. However, the response to glucagon within each group did not appear to be related to Circulation, Volrume XXXIX, January 1969 the severity of the hemodynamic derangement at rest, suggesting that the quantitative differences in response between groups occurred primarly as a result of the administration of different doses.
The ability of glucagon to elevate blood glucose is, of course, well recognized. Its effect on serum potassium, however, appears to be less well recognized. A decrease in serum potassium would be expected in view of its known effect on blood glucose and insulin secretion, and a decrease in plasma potassium at the 30-min period did accompany the increase in blood glucose in each individual in whom it was determined, these effects being more marked after 5 mg than after 3 mg. A similar decrease in plasma potassium was observed by Parmley and associates. 6 These results suggest that the intravenous administration of glucagon to patients receiving digitalis may promote the development of digitalis-induced arrhythmias. Several of the patients in this study were receiving digitalis, including the patient in whom plasma potassium decreased from 4.4 to 2.8 mEq/L; however, no arrhythmias were observed.
The clinical usefulness of glucagon remains to be determined. An increase in cardiac output at a lower filling pressure, as occurred in the majority of these patients, certainly is a desirable goal in the treatment of low output congestive heart failure. However, the ability of glucagon to produce such an effect is not universal, and when this effect does occur, it is relatively short-lived. Furthermore, the development of nausea in four of the six patients receiving 5 mg indicates that this is near the maximum dose which can be tolerated when given over a short period of time. Also the effect of glucagon on cardiac output and filling pressures appears to be significantly less than that of isoproterenol whose positive inotropic action has proved useful under certain clinical conditions. In this regard, however, it must be appreciated that this was a near maximal dose of isoproterenol for these patients, and it is unlikely that this dose could have been administered for an indefinite period of time or that its effect would have been sustained. Since any agent which can produce improvement in myocardial function, albeit short lived, without producing arrhythmias is potentially useful, further studies on patients with different types of heart disease and under different clinical conditions are warranted.
